Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax combined with tamoxifen in relapsed/refractory diffuse large B-cell lymphoma
NL-OMON20687Not yet recruiting
- Sponsor
- University Medical Center Groningen
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of venetoclax and tamoxifen in diffuse large B-cell lymphoma (DLBCL) and large-cell lymphoma, sponsored by University Medical Center Groningen. Planned start May 2021; status: not yet recruiting.
02
Drugs
venetoclaxtamoxifen
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphoma
Beyond the preview
Go deeper on NL-OMON20687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20687.